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Abstract
Background—The long-term antibody response to measles vaccine (MV) administered at age 6 
months with or without subsequent doses is not well documented.
Methods—Measles serum antibody responses were evaluated after a supplemental dose of 
measles vaccine (sMV) administered at a median age of 20 months among Malawian children who 
had previously received 2 doses of measles vaccine (MV) at ages 6 and 9 months (HIV-infected 
and random sample of HIV-uninfected) or 1 dose at age 9 months (random sample of HIV-
uninfected). We compared measles antibody seropositivity between groups by enzyme linked 
immunoassay and seroprotection by plaque reduction neutralization geometric mean 
concentrations.
Results—Of 1756 children enrolled, 887 (50.5%) received a sMV dose following MV at 9 
months of age and had specimens available after sMV receipt, including 401 HIV-uninfected 
children who received one MV dose at 9 months, 464 HIV-uninfected and 22 HIV-infected 
children who received two doses of MV at ages 6 and 9 months. Among HIV-uninfected children, 
protective levels of antibody were found post sMV in 90–99% through ages 24–36 months and 
were not affected by MV schedule. Geometric mean concentration levels of measles antibody were 
significantly increased post-sMV among those HIV-uninfected children previously non-responsive 
to vaccination. Among HIV-infected children, the proportion seroprotected increased initially but 
by 9 months post-sMV was no higher than pre-sMV.
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Conclusions—Our findings support early 2-dose MV to provide measles immunity for young 
infants without risk of interference with antibody responses to subsequent MV doses administered 
as part of SIAs.
Keywords
Measles vaccine; HIV; Supplementary immunization activity; Antibody response; Neutralizing 
antibody
1. Background
The World Health Organization (WHO) recommends that children be vaccinated with at 
least two doses of measles vaccine (MV). In areas of the world with high rates of both HIV 
and measles infection, the World Health Organization recommends that a first MV dose may 
be offered as early as age 6 months of age, with two additional doses administered through 
routine services and/or supplemental immunization activities (SIAs) according to the 
national immunization schedule [1]. Strategies to introduce MV at ages younger than age 9 
months must weigh the potential for a lower antibody response due to interference of 
maternal antibodies and possibly immature immune systems with the risk of developing 
measles in the first year of life [2,3]. Data on the long-term antibody response to MV 
administered at age 6 months with or without subsequent doses are inconclusive [4–6]. We 
have previously demonstrated protective levels of antibody more than a year post-
vaccination among HIV-uninfected children in Malawi who were randomized to receive 
either one MV dose at age 9 months or two MV doses at ages 6 and 9 months [7,8]. 
However, the two-dose MV schedule did not appear to improve protection among HIV-
infected children beyond that reported by prior studies of vaccination of HIV-infected 
children at 9 months of age [9]. During the study, a SIA was conducted, which afforded the 
opportunity to compare antibody responses to the supplemental dose of measles vaccine 
(sMV) for the two vaccination strategies.
2. Methods
Malawi study of measles vaccination in HIV-infected and -uninfected children
The study design and detailed methods have been described in previous publications [7,8]. 
Briefly, the study was conducted in Blantyre, Malawi from August 2000 through March 
2003, at which time the HIV infection prevalence among women of child bearing age was 
approximately 33% [10]. During the infant’s 14-week routine immunization visit at the 
Ndirande Health Center, 1327 children born to HIV-uninfected mothers were enrolled and 
randomized to receive either two doses of standard-titer Edmonston–Zagreb MV (Berna 
Biotech) at ages 6 and 9 months or one dose at age 9 months; all 429 children born to HIV-
infected mothers were assigned to the 2-dose MV group. Adverse events were assessed 7 
and 21 days after receipt of any MV dose. Blood was drawn and clinical information was 
collected at enrollment and during each follow-up appointment scheduled at ages 6, 9, 12, 
20, 24, 30, and 36 months. Clinical information was also obtained on outpatient clinic visits, 
hospitalizations, and deaths. Antiretroviral therapy was not available in the public sector at 
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the time of this study. Previous publications reported the detailed methods, clinical follow-
up, loss to follow-up, and the antibody response to early and 9-month MV doses [7,8].
2.1. Evaluation of supplemental measles vaccination
In August of 2002, a nationwide measles vaccination SIA for all children ages 9–59 months 
was conducted by the Malawi Ministry of Health, in partnership with WHO, and the United 
Nations Children’s Fund. At the time of the SIA, there were no recently reported measles 
cases near the study region of Malawi, thus approval was received by the Institutional 
Review Boards and Ministry of Health for parents of children in the measles study aged <20 
months to be given the option to defer sMV until age 20–24 months, the planned follow-up 
age for study children. A revised consent form was developed for the parents/guardians 
explaining the option to defer vaccination in the SIA. Parents/guardians presenting children 
for vaccination during the SIA were referred to the study clinic (which was located at a 
government health center) for sMV receipt when campaign staff recognized the study 
participation stamp in the immunization card. Therefore children received sMV through the 
SIA campaign directly, the study clinic during the SIA, or a follow up study clinic visit. 
Parent/guardian report and immunization cards were used to document sMV receipt at the 
SIA.
2.2. Measles antibody and HIV detection
Measles serologic testing by enzyme immunoassay (EIA, Trinity Biotech) and HIV-testing 
by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) were performed at 
the Centers for Disease Control and Prevention as described previously [7]. To account for 
documented reductions in EIA sensitivity in serum specimens with lower levels of measles 
antibody compared with the gold standard plaque reduction neutralization (PRN) [4], 
specimens from all HIV-infected children and a random selection of HIV-uninfected 
children with follow-up through the 12 and 24 month study visits were also tested for 
measles antibody by plaque reduction neutralization (PRN) at the Food and Drug 
Administration [8]. Children with specimens randomly selected for PRN testing were 
representative of the total study population. We defined seropositivity as an immune status 
ratio >1.1 from the measles EIA assay and a seroprotective antibody titer as a measles PRN 
antibody titer ≥120 mIU/mL relative to WHO II Reference serum, 66/202 [11].
2.3. Data analysis
In previous publications, children’s data were censored at the time of sMV receipt. In the 
present analysis, we included children who had received sMV >3 months after their routine 
9-month MV dose and had data available from at least one specimen collected >28 days 
following sMV receipt. For each child, we used the specimen taken on the date of sMV or 
the most recent specimen available prior to sMV to determine the pre-sMV measles antibody 
levels. We categorized post-sMV specimens according to the number of months since sMV 
receipt: <3 months, 3 to <6 months, 6 to <9 months, and >9 months. Seven children who 
seroconverted to HIV after age 12 months were analyzed separately.
Among HIV-uninfected children, we compared responses to sMV among those who had 
previously received 1- or 2-doses of MV. We also compared responses among HIV-infected 
Fowlkes et al. Page 3
Vaccine. Author manuscript; available in PMC 2017 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and -uninfected children. For each time point, we calculated the proportion seropositive by 
EIA and seroprotected by PRN and the geometric mean concentration (GMC) of the measles 
neutralizing antibody levels. The proportion of measles seropositive or seroprotected 
patients were compared across study groups at each time point using the pairwise chi-square 
comparisons or Fisher’s exact tests at time points with a small sample size. The log-
transformed neutralizing antibody titers at different time points were compared within and 
between study groups using a one way analysis of variance and pairwise t-tests to identify 
specific group differences. Stata, version 12 (College Station, TX) was used for analysis.
3. Results
Of 1756 children originally enrolled, 1060 (60.4%) children remained in the study through 
receipt of the sMV; 887 (83.7%) had antibody data available after sMV receipt. Children in 
all study groups received sMV at approximately age 20 months, a median of 11 months 
(interquartile range 9.5–14.6) after receipt of the 9-month routine MV dose (Table 1). The 
demographic characteristics of children included in this sMV evaluation were similar to the 
total study population (data not shown) and did not differ among HIV-uninfected study 
groups (Table 2) [7]. Due to the selection of children for the present study based on the 
availability of specimen test results following sMV, which occurred during the children’s 
final year of participation, study attrition and mortality rates did not differ according to HIV-
infection status; however, as previously reported, HIV-infected children were lost to follow-
up in the full study by age 20 months significantly more frequently, with mortality as the 
leading cause [8]. Consistent with the evaluation of primary vaccination, no serious adverse 
events were identified following sMV, and rates of outpatient clinic visits, hospitalizations, 
and deaths were similar 30 days before and 30 days after sMV for each study group (data 
not shown). A significantly higher proportion of HIV-uninfected children received sMV 
through the SIA compared with HIV-infected children (29.7% [263/865] vs. 9.1% [2/22]); 
however, no differences in antibody response was detected according to SIA vs. study clinic 
sMV.
Children without HIV infection
Prior to sMV, approximately 81% of HIV-uninfected 1- and 2-MV dose recipients were 
seropositive by EIA, and approximately 89% were seroprotected according to PRN testing 
(Table 1). Both the sensitivity and specificity of the EIA relative to the PRN assay were 91% 
(95% CI: 89.9–92.7% and 89.3%–93.2%, respectively) [8]. The pre-sMV measles 
neutralizing antibody GMC did not differ significantly according to vaccine schedule (Fig. 
1).
At each time point measured after sMV, the proportion of children seropositive was 
significantly higher than pre-sMV; most HIV-uninfected children remained both measles 
seropositive and seroprotected through the end of the study. The measles antibody GMC 
rose sharply after vaccination, showing a 3-fold increase (Fig. 1), but then fell quickly again 
such that by >9 months post-sMV the GMCs were only 1.3 and 1.4 times higher than the 
pre-sMV values among 1- and 2-MV dose recipients, respectively. Further evaluation of 
GMCs according to children’s pre-sMV antibody level demonstrated that pre-sMV 
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seronegative children maintained a 4-fold or higher GMC compared with their pre-sMV 
values through >9 months post-sMV (pre-sMV GMC range 44–80 mIU/mL vs. >9 months 
post-sMV GMC range 161–742; p < 0.001, Fig. 2). By contrast, it was the pre-sMV measles 
antibody positive children whose measles antibody level at >9 months post-sMV had fallen 
to levels comparable to the pre-sMV values. No significant differences in the measles 
antibody GMC between 1- and 2-MV dose groups were detected at any time point post-
sMV.
Prior to sMV, HIV-uninfected females in both the 1- and 2-dose MV groups had 
significantly higher measles antibody GMCs than males (data not shown); similar findings 
were previously reported [7]. Following sMV, no gender differences were detected at any 
time point for any study group. In addition, measles antibody response to sMV did not vary 
according to nutritional status.
3.1. HIV-infected children
Of 45 HIV-infected children remaining in the study at 12 months of age, 28 (62.2%) met 
inclusion criteria for the sMV evaluation. Only 38.1% of HIV-infected children were 
seropositive pre-sMV—significantly lower (p < 0.001) than other study groups (Table 1, Fig. 
1). Among 15 HIV-infected children with specimens collected 3–6 months following sMV, a 
significant increase in the GMC (270 mIU/mL) and the proportion seropositive and sero-
protected (66.7% and 73.3%, respectively, < 0.05) was observed. However, this increase in 
measles antibody levels was not sustained, as indicated by seropositivity and seroprotection 
rates at or below 40% at later time points. The pattern of an initial rise in GMCs followed by 
rapid fall post-sMV was similar to that in the HIV-uninfected groups except that even in 
those seronegative pre-sMV, a sustained increase in antibody level was not seen (Fig. 2). The 
proportion of HIV-infected children seropositive and seroprotected did not vary at any time 
point by nutritional status indicators; however, the pre-sMV antibody titers were 
significantly lower among underweight children compared with other weight categories 
(GMC 76 [95%CI: 4–166] vs. 204 [95% CI: 33–327], p < 0.05).
Among the 7 children excluded from other analyses due to HIV seroconversion after age 12 
months, 5 received sMV after sero-converting to HIV. At the time of sMV, 4 (57.1%) of 
these children were measles positive by EIA, 5 (71.4%) were seroprotected, and the GMC 
was 225.0 mIU/mL. Within six months following sMV, 5 of 6 (83.3%) children were 
seropositive and 5 (83.3%) children were seroprotected; however, it was not the same child 
testing negative by EIA and PRN. After >9 months following sMV, only 2 of 5 children 
were seropositive by EIA, although three of four with PRN results available were still 
considered seroprotected and the GMC was 400 mIU/mL.
4. Discussion
Among HIV-uninfected children, we observed a sustained measles antibody response to 
sMV among previous MV non-responders that was similar for children who had received 
either a routine single MV dose at age 9 months or an early, 2-dose MV schedule at ages 6 
and 9 months. Consistent with our findings following the 1- and 2-dose MV receipt, we 
found after sMV that when measured by EIA, measles seropositivity rates were lower 
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among 2-dose than 1-dose recipients, but by the gold standard PRN, rates of seropositivity 
and seroprotection did not differ significantly by vaccination schedule [8].
We were able to utilize the post-sMV period to systematically evaluate the antibody 
response to sMV. It is reassuring that receipt of an early MV dose at age 6 months did not 
adversely affect responses elicited by a routine dose of MV at age 9 months nor the sMV 
given later among HIV-uninfected children. These findings are consistent with studies that 
found no evidence of interference to sMV subsequent to an early dose of MV [4,12], and 
support the approach of recent studies that indicate early MV benefits in reducing infant 
hospitalization and mortality [13,14]. The sMV clearly increased the proportion of children 
seroprotected against measles. Among HIV-uninfected children, a sharp rise in the antibody 
titer was observed in the months immediately following sMV, and was maintained among 
previous MV non-responders. The observed titer increase among children who were immune 
prior to sMV was transient and declined by 9 months post-sMV. This corresponds with 
previous work showing that a boost from additional doses of measles vaccine on measles 
antibody levels may be relatively short-lived among children who had previously shown an 
immune response to vaccination [15].
Among HIV-infected children, the sMV led to a transient boost in antibodies which waned 
rapidly over time, even in those who were not seroprotected pre-sMV. Neither the proportion 
seroprotected nor the GMC was significantly higher by 9 months post-sMV than pre-sMV. 
Our findings were consistent with previous studies which demonstrate the rapid decline in 
vaccine-induced measles antibody titers and a lack of sustained response to MV in HIV-
infected children [16]. The very small number of children who developed HIV infection 
subsequent to primary measles vaccination maintained better measles positivity and 
seroprotective levels of antibody compared with children who were HIV-infected at the time 
of primary vaccination. However, the measles antibody levels for these late HIV 
seroconverters were diminished in comparison with HIV-uninfected children. A review of 
recent studies indicated that revaccination after immune reconstitution via antiretroviral 
therapy can result in sustained immune responses to measles [17].
The sMV evaluation had limitations, since the original design did not account for the SIA. 
As a result, the <3 months post-sMV time period established for early immune response 
evaluation contained small numbers of children in each group. However, among HIV-
uninfected child groups, subsequent time periods were well powered for detection of 
differences. Due to high mortality and dropout rates among HIV-infected children, our sMV 
evaluations included only small numbers of HIV-infected children. Finally, our study was 
conducted prior to routine use of antiretroviral medications and CD4 counts of the children 
were unavailable, precluding an evaluation of their specific effects on MV antibody 
responses.
For WHO regions to achieve their goal for measles elimination by 2020, an estimated 
population immunity of 93–95% must be maintained. Our findings provide support for the 
WHO measles vaccine delivery strategy that provides an additional opportunity for measles 
vaccination, and confirm that the sMV is safe and effective for children receiving either 
early, 2-dose or routine, 1-dose MV. Our findings further suggest that early MV 
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administration can provide measles immunity to a substantial proportion of susceptible 
young infants without interference of antibody responses to subsequent MV doses 
administered as part of SIAs.
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Fig. 1. 
Geometric mean concentration of measles antibody before and after a supplemental dose of 
measles vaccine (sMV) among children randomized to receive measles vaccination (MV) at 
9 months or 6 and 9 months of age by HIV infection status. No HIV-exposed children were 
randomized to receive MV at 9 months only. The protective level of measles antibody (120 
mIU/mL) is relative to WHO II Reference Serum 66/202.
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Fig. 2. 
Geometric mean concentration of measles antibody before and after a supplemental dose of 
measles vaccine (sMV) according to measles seropositivity pre-sMV, by vaccine schedule 
and HIV infection status.
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